Загрузка...
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
All current regimens for treating ovarian cancer center around carboplatin as standard first line. The HSP90 inhibitor ganetespib is currently being assessed in advanced clinical oncology trials. Thus, we tested the combined effects of ganetespib and carboplatin on a panel of 15 human ovarian cancer...
Сохранить в:
| Опубликовано в: : | Cell Death Differ |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5299713/ https://ncbi.nlm.nih.gov/pubmed/27834954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2016.124 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|